5 September 2003

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
A61K 33/00, A61P 25/00

A1

(11) International Publication Number: WO 00/53192

(43) International Publication Date: 14 September 2000 (14.09.00)

(21) International Application Number: PCT/EP00/02025

(22) International Filing Date: 8 March 2000 (08.03.00)

(30) Priority Data:
199 10 986.9 11 March 1999 (11.03.99) DE

(71) Applicant *(for all designated States except US)*: AGA AB [SE/SE]; S-181 81 Lidingö (SE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: PETZELT, Christian [DE/DE]; Herderstrasse 15, D-10626 Berlin (DE). KOX, Wolfgang, J. [DE/DE]; Krottnaurerstrasse 43, D-14129 Berlin (DE).

(74) Agent: SCHÜSSLER, Andrea; Huber & Schüssler, Truderinger Str. 246, D-81825 München (DE).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: USE OF XENON FOR TREATING NEUROINTOXICATIONS

(57) Abstract

The present invention relates to the use of xenon or xenon gas mixtures for treating neurointoxications. In particular, the present invention is directed to such a xenon use in which the neurointoxication is caused by a neurotransmitter excess. Xenon can reduce the release of neurotransmitters, particularly dopamine, which are caused e.g. by hypoxic situations such as an apoplexy or a craniocerebral trauma. A preparation containing xenon can also be used as therapeutic agent in the case of depressions, schizophrenia and Parkinson's disease, in which the neurotransmitter equilibrium is also disturbed. The application by inhalation is simple and the harmlessness of xenon is already been proved by its use as anesthetic agent.

162162

G00001